The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ICML 2023 | BTK inhibitors for R/R MCL: current uses and insights from the ViPOR study
Christopher Melani, MD, National Institutes of Health, Bethesda, MD, comments on the success of Bruton’s tyrosine kinase (BTK) inhibitors in the treatment of non-Hodgkin lymphoma (NHL), particularly relapsed/refractory mantle cell lymphoma (R/R MCL). Dr Melani begins by discussing the safety and efficacy of approved BTK inhibitors in R/R MCL, and compares the progression-free survival (PFS) data for these monotherapies to the combination of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR; NCT03223610). Dr Melani explains the promising results from the ViPOR study and shares some perspectives on the future of BTK inhibitors in MCL. This interview took place at the 17th International Conference on Malignant Lymphoma (ICML), held in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
